Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Legend Biotech (LEGN) Long-Term Deferred Tax: 2019-2021

  • Legend Biotech's Long-Term Deferred Tax fell 25.98% to $22.8 million in Q4 2021 from the same period last year, while for Dec 2021 it was $22.8 million, marking a year-over-year decrease of 25.98%. This contributed to the annual value of $22.8 million for FY2021, which is 25.98% down from last year.
  • As of Q4 2021, Legend Biotech's Long-Term Deferred Tax stood at $22.8 million, which was down 25.98% from $30.8 million recorded in Q4 2020.
  • In the past 5 years, Legend Biotech's Long-Term Deferred Tax registered a high of $30.8 million during Q4 2020, and its lowest value of $5.7 million during Q4 2019.
  • Its 3-year average for Long-Term Deferred Tax is $19.8 million, with a median of $22.8 million in 2021.
  • Per our database at Business Quant, Legend Biotech's Long-Term Deferred Tax surged by 438.86% in 2020 and then decreased by 25.98% in 2021.
  • Quarterly analysis of 3 years shows Legend Biotech's Long-Term Deferred Tax stood at $5.7 million in 2019, then spiked by 438.86% to $30.8 million in 2020, then decreased by 25.98% to $22.8 million in 2021.
  • Its last three reported values are $22.8 million in Q4 2021, $30.8 million for Q4 2020, and $5.7 million during Q4 2019.